Literature DB >> 12853397

T-cell immune response assessment as a complement to serology and intranasal protection assays in determining the protective immunity induced by acellular pertussis vaccines in mice.

C M Ausiello1, R Lande, P Stefanelli, C Fazio, G Fedele, R Palazzo, F Urbani, P Mastrantonio.   

Abstract

The relative value of antibodies and/or T-cell immune responses to Bordetella pertussis antigens in the immunity induced by acellular pertussis (aP) vaccines is still an open issue, probably due to the incomplete knowledge on the mechanisms of protective immunity to pertussis. The relevance of T-cell immune responses in protection from pertussis has been demonstrated in murine and human models of infection; thus, in this study, the ability of different vaccine preparations of three component (pertussis toxin, filamentous hemagglutinin, and pertactin) aP vaccines to induce T-cell responses was investigated in mice. All vaccine preparations examined passed the immunogenicity control test, based on antibody titer assessment, according to European Pharmacopoeia standards, and protected mice from B. pertussis intranasal challenge, but not all preparations were able to prime T cells to pertussis toxin, the specific B. pertussis antigen. In particular, one vaccine preparation was unable to induce proliferation and gamma interferon (IFN-gamma) production while the other two gave borderline results. The evaluation of T-cell responses to pertussis toxin antigen may provide information on the protective immunity induced by aP vaccines in animal models. Considering the critical role of the axis interleukin-12-IFN-gamma for protection from pertussis, our results suggest that testing the induction of a key protective cytokine such as IFN-gamma could be an additional tool for the evaluation of the immune response induced by aP vaccines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12853397      PMCID: PMC164277          DOI: 10.1128/cdli.10.4.637-642.2003

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  45 in total

1.  Cell-mediated immune response of healthy adults to Bordetella pertussis vaccine antigens.

Authors:  C M Ausiello; R Lande; A la Sala; F Urbani; A Cassone
Journal:  J Infect Dis       Date:  1998-08       Impact factor: 5.226

2.  Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children.

Authors:  M Ryan; G Murphy; E Ryan; L Nilsson; F Shackley; L Gothefors; K Oymar; E Miller; J Storsaeter; K H Mills
Journal:  Immunology       Date:  1998-01       Impact factor: 7.397

3.  Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine.

Authors:  F Zepp; M Knuf; P Habermehl; J H Schmitt; C Rebsch; P Schmidtke; R Clemens; M Slaoui
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

4.  Acellular vaccines containing reduced quantities of pertussis antigens as a booster in adolescents.

Authors:  N N Tran Minh; Q He; A Ramalho; A Kaufhold; M K Viljanen; H Arvilommi; J Mertsola
Journal:  Pediatrics       Date:  1999-12       Impact factor: 7.124

Review 5.  Recommendations are needed for adolescent and adult pertussis immunisation: rationale and strategies for consideration.

Authors:  M Campins-Martí; H K Cheng; K Forsyth; N Guiso; S Halperin; L M Huang; J Mertsola; G Oselka; J Ward; C H Wirsing von König; F Zepp
Journal:  Vaccine       Date:  2001-12-12       Impact factor: 3.641

6.  An aerosol challenge model of Bordetella pertussis infection as a potential bioassay for acellular pertussis vaccines.

Authors:  D K Xing; R G Das; L Williams; C Canthaboo; J Tremmil; M J Corbel
Journal:  Vaccine       Date:  1999-02-12       Impact factor: 3.641

7.  Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. The Progetto Pertosse-CMI Working Group.

Authors:  A Cassone; C M Ausiello; F Urbani; R Lande; M Giuliano; A La Sala; A Piscitelli; S Salmaso
Journal:  Arch Pediatr Adolesc Med       Date:  1997-03

8.  Role of gamma interferon in natural clearance of Bordetella pertussis infection.

Authors:  J Barbic; M F Leef; D L Burns; R D Shahin
Journal:  Infect Immun       Date:  1997-12       Impact factor: 3.441

9.  Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on induction of cell-mediated immunity.

Authors:  K Redhead; J Watkins; A Barnard; K H Mills
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

10.  Defective response to T cell mitogens in mice injected with human immunodeficiency virus type 1-infected U937 cells.

Authors:  C M Ausiello; P Sestili; C Locardi; M Logozzi; P Rizza; E Parlanti; L Yang; A Modica; A Modesti; P Musiani
Journal:  J Gen Virol       Date:  1994-10       Impact factor: 3.891

View more
  6 in total

1.  Bordetella pertussis proteins dominating the major histocompatibility complex class II-presented epitope repertoire in human monocyte-derived dendritic cells.

Authors:  Rachel M Stenger; Hugo D Meiring; Betsy Kuipers; Martien Poelen; Jacqueline A M van Gaans-van den Brink; Claire J P Boog; Ad P J M de Jong; Cécile A C M van Els
Journal:  Clin Vaccine Immunol       Date:  2014-03-05

2.  Delayed BCG vaccination results in minimal alterations in T cell immunogenicity of acellular pertussis and tetanus immunizations in HIV-exposed infants.

Authors:  Anna K Blakney; Christophe Toukam Tchakoute; Anneke C Hesseling; Elvis B Kidzeru; Christine E Jones; Jo-Ann S Passmore; Donald L Sodora; Clive M Gray; Heather B Jaspan
Journal:  Vaccine       Date:  2015-08-07       Impact factor: 3.641

3.  Immunogenicity of a whole-cell pertussis vaccine with low lipopolysaccharide content in infants.

Authors:  Tatiane Queiroz Zorzeto; Hisako Gondo Higashi; Marcos Tadeu Nolasco da Silva; Emilia de Faria Carniel; Waldely Oliveira Dias; Vanessa Domingues Ramalho; Taís Nitsch Mazzola; Simone Corte Batista Souza Lima; André Moreno Morcillo; Marco Antonio Stephano; Maria Angela Reis de Góes Antonio; Maria de Lurdes Zanolli; Isaias Raw; Maria Marluce dos Santos Vilela
Journal:  Clin Vaccine Immunol       Date:  2009-03-04

Review 4.  Vaccine-Induced Cellular Immunity against Bordetella pertussis: Harnessing Lessons from Animal and Human Studies to Improve Design and Testing of Novel Pertussis Vaccines.

Authors:  Anja Saso; Beate Kampmann; Sophie Roetynck
Journal:  Vaccines (Basel)       Date:  2021-08-07

5.  Production and characterization of recombinant pertactin, fimbriae 2 and fimbriae 3 from Bordetella pertussis.

Authors:  Yinghua Xu; Yaying Wang; Yajun Tan; Huajie Zhang; Lijie Wu; Lichan Wang; Qiming Hou; Shumin Zhang
Journal:  BMC Microbiol       Date:  2009-12-29       Impact factor: 3.605

6.  International Bordetella pertussis assay standardization and harmonization meeting report. Centers for Disease Control and Prevention, Atlanta, Georgia, United States, 19-20 July 2007.

Authors:  M L Tondella; G M Carlone; N Messonnier; C P Quinn; B D Meade; D L Burns; J D Cherry; N Guiso; E L Hewlett; K M Edwards; D Xing; A Giammanco; C H Wirsing von König; L Han; L Hueston; J B Robbins; M Powell; C M Mink; J T Poolman; S W Hildreth; F Lynn; A Morris
Journal:  Vaccine       Date:  2008-12-09       Impact factor: 3.641

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.